| Literature DB >> 31367691 |
Susanne M Henning1, Jieping Yang1, Shih Lung Woo1, Ru-Po Lee1, Jianjun Huang1, Anna Rasmusen1, Catherine L Carpenter1, Gail Thames1, Irene Gilbuena1, Chi-Hong Tseng2, David Heber1, Zhaoping Li1.
Abstract
BACKGROUND: Avocados contain fiber, lutein, and vitamin E, and they are a rich source of MUFAs. The effect of including an avocado daily as part of a hypocaloric weight-loss diet on weight loss is not known.Entities:
Keywords: avocado; clinical trial; hepatic growth factor; inflammation; intestinal microbiota; satiety; weight loss
Year: 2019 PMID: 31367691 PMCID: PMC6658913 DOI: 10.1093/cdn/nzz068
Source DB: PubMed Journal: Curr Dev Nutr ISSN: 2475-2991
Baseline demographics of study participants
| CTRL ( | AVO ( | |
|---|---|---|
| Sex, % women | 74 | 83 |
| Age, y | 36.4 ± 10.8 | 42.5 ± 12.7 |
| Weight, kg | 83.2 ± 15.8 | 83.2 ± 10.7 |
| BMI, kg/m2 | 30.0 ± 3.7 | 30.1 ± 3.2 |
| Total body fat, % | 38.3 ± 8.5 | 41.2 ± 5.1 |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value; *P < 0.05. AVO, Hass avocado group; CTRL, control group.
FIGURE 1Body weight changes of participants in the AVO and CTRL groups from baseline to week 12. Data are means ± SDs, n = 27 (CTRL) and n = 24 (AVO). ANCOVA model was used to compare outcomes adjusted for baseline value. *P < 0.05. AVO, Hass avocado group; CTRL, control group.
Change of body composition and satiety from baseline to week 12
| CTRL ( |
| AVO ( |
|
| |
|---|---|---|---|---|---|
| Weight, kg | −2.6 ± 3.6 | <0.001 | −2.3 ± 2.0 | <0.001 | NS |
| BMI, kg/m2 | −0.93 ± 1.26 | <0.001 | −0.84 ± 0.76 | <0.001 | NS |
| Body fat, % | −1.51 ± 1.60 | <0.001 | −1.13 ± 2.25 | 0.004 | NS |
| Visceral adipose tissue, g | −87.4 ± 216 | 0.025 | −81.2 ± 118 | 0.01 | NS |
| Satiety score | −0.45 ± 1.06 | 0.01 | −0.19 ± 0.75 | NS | NS |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value; P < 0.05. AVO, Hass avocado group; CTRL, control group; NS, not significant.
FIGURE 2Satiety score changes of participants in the AVO and CTRL groups from baseline to week 12. Data are means ± SDs, n = 27 (CTRL) and n = 24 (AVO). ANCOVA model was used to compare outcomes adjusted for baseline value. *P < 0.05. AVO, Hass avocado group; CTRL, control group.
Change of serum concentration of metabolic and inflammatory markers from baseline to week 12
| Change from baseline | CTRL ( |
| AVO ( |
|
|
|---|---|---|---|---|---|
| Glucose, mg/dL | −7.52 ± 10.76 | 0.001 | −0.18 ± 10.12 | NS | 0.024 |
| Insulin, pg/mL | 50.1 ± 259.9 | NS | 35.8 ± 144.0 | NS | NS |
| Total cholesterol, mg/dL | −11.1 ± 31.4 | 0.04 | −4.73 ± 23.4 | NS | NS |
| HDL cholesterol, mg/dL | −1.4 ± 9.0 | NS | −1.5 ± 6.1 | NS | NS |
| LDL cholesterol, mg/dL | −10.4 ± 32.5 | NS | −1.1 ± 27.5 | NS | NS |
| Triglyceride, mg/dL | −10.9 ± 39.6 | NS | −25.5 ± 37.4 | 0.001 | NS |
| NGF, pg/mL | 0.4 ± 1.2 | NS | −0.1 ± 0.8 | NS | NS |
| IL-6, pg/mL | 0.24 ± 0.95 | NS | −0.04 ± 1.13 | NS | NS |
| Leptin, ng/mL | −2.1 ± 8.5 | NS | −1.3 ± 7.0 | NS | NS |
| HGF, pg/mL | 4.1 ± 38.5 | NS | −21.4 ± 39.3 | 0.02 | 0.045 |
| MCP-1, pg/mL | 6.3 ± 30.5 | NS | 5.3 ± 25.1 | NS | NS |
| TNF-α, pg/mL | 0.2 ± 0.5 | NS | 0.2 ± 0.6 | NS | NS |
| IL-1β, pg/mL | 0.03 ± 0.30 | NS | −0.10 ± 0.26 | 0.08 | 0.07 |
| CRP, µg/mL | 2.2 ± 13.7 | NS | −5.2 ± 17.2 | 0.085 | 0.074 |
| Adiponectin, µg/mL | 2.0 ± 34.4 | NS | 4.4 ± 61.4 | NS | NS |
| Resistin, ng/mL | −0.5 ± 16.4 | NS | 6.2 ± 32.8 | NS | NS |
| PAI, ng/mL | −10.9 ± 65.5 | NS | −6.6 ± 53.3 | NS | NS |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value. AVO, Hass avocado group; CRP, C-reactive protein; CTRL, control group; HGF, hepatic growth factor; MCP-1, monocyte chemoattractant protein-1; NGF, nerve growth factor; NS, not significant; PAI, plasminogen activator inhibitor-1.
Changes in gut microbiota phylum composition from baseline to week 12 in the AVO and CTRL groups as percentage of total bacteria count
| CTRL ( | AVO ( | CTRL vs. AVO | |||||
|---|---|---|---|---|---|---|---|
| Baseline | Final |
| Baseline | Final |
|
| |
| Firmicutes | 61.29 ± 11.00 | 57.11 ± 8.76 | 0.084 | 53.91 ± 10.02 | 56.79 ± 9.70 | 0.069 | 0.016 |
| Bacteriodetes | 26.94 ± 9.83 | 32.37 ± 10.57 | 0.053 | 34.88 ± 14.41 | 32.33 ± 12.21 | NS | 0.023 |
| Actinobacteria | 7.24 ± 6.07 | 7.15 ± 6.42 | NS | 7.59 ± 7.86 | 6.71 ± 4.68 | NS | NS |
| Euryarchaeota | 1.76 ± 2.95 | 1.33 ± 1.88 | NS | 1.05 ± 2.42 | 1.08 ± 2.17 | NS | NS |
| Verrucomicrobia | 0.75 ± 1.90 | 0.55 ± 0.98 | NS | 1.23 ± 1.73 | 1.86 ± 2.19 | NS | NS |
| Proteobacteria | 1.09 ± 1.61 | 1.05 ± 1.35 | NS | 0.89 ± 1.22 | 0.86 ± 0.78 | NS | NS |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value. AVO, Hass avocado group; CTRL, control group; NS, not significant.
Changes in gut microbiota family composition from baseline to week 12 in the AVO and CTRL groups as percentage of total bacteria count
| CTRL ( | AVO ( | CTRL vs. AVO | ||||||
|---|---|---|---|---|---|---|---|---|
| Family | Phyla | Baseline | Final |
| Baseline | Final |
|
|
| Bacteroidaceae | Bacteroidetes | 17.27 ± 11.31 | 21.59 ± 12.36 | 0.046 | 23.37 ± 12.55 | 19.82 ± 10.22 | NS | 0.012 |
| Ruminococcaceae | Firmicutes | 20.03 ± 6.02 | 19.82 ± 5.28 | NS | 18.54 ± 7.33 | 20.79 ± 6.68 | 0.056 | NS |
| Lachnospiraceae | Firmicutes | 16.56 ± 5.89 | 14.50 ± 4.78 | 0.033 | 15.37 ± 4.82 | 14.30 ± 4.00 | NS | NS |
| Clostridiaceae | Firmicutes | 8.77 ± 3.18 | 7.92 ± 3.74 | NS | 8.28 ± 3.42 | 9.56 ± 3.74 | NS | 0.061 |
| Erysipelotrichaceae | Firmicutes | 3.32 ± 4.49 | 2.62 ± 3.68 | NS | 1.98 ± 4.05 | 2.63 ± 4.30 | NS | 0.046 |
| Prevotellaceae | Bacteroidetes | 2.59 ± 5.8 | 2.1 ± 5.2 | NS | 0.25 ± 0.45 | 0.64 ± 1.7 | 0.08 | NS |
| Veillonellaceae | Firmicutes | 0.51 ± 0.69 | 0.85 ± 1.27 | NS | 1.34 ± 3.26 | 1.48 ± 3.33 | 0.023 | NS |
| Sutterellaceae | Proteobacteria | 0.27 ± 0.62 | 0.35 ± 0.92 | NS | 0.14 ± 0.14 | 0.34 ± 0.33 | 0.005 | NS |
| Oxalobacteraceae | Proteobacteria | 0.010 ± 0.020 | 0.150 ± 0.576 | 0.048 | 0.033 ± 0.056 | 0.050 ± 0.102 | NS | NS |
| Oscillatoriales | Cyanobacteria | 0.013 ± 0.041 | 0.007 ± 0.029 | 0.03 | 0.019 ± 0.056 | 0.002 ± 0.005 | NS | NS |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value. AVO, Hass avocado group; CTRL, control group; NS, not significant.
Changes in gut microbiota genus composition from baseline to week 12 in the AVO and CTRL groups as percentage of total bacteria count
| CTRL ( | AVO ( | CTRL vs. AVO | ||||||
|---|---|---|---|---|---|---|---|---|
| Genus | Phyla | Baseline | Final |
| Baseline | Final |
|
|
|
| Bacteroidetes | 17.27 ± 11.31 | 21.59 ± 12.36 | 0.043 | 23.37 ± 12.55 | 19.82 ± 10.22 | NS | 0.012 |
|
| Firmicutes | 8.75 ± 3.17 | 7.87 ± 3.70 | NS | 8.2 ± 3.41 | 9.51 ± 3.72 | NS | 0.05 |
|
| Firmicutes | 0.39 ± 0.61 | 0.61 ± 1.15 | NS | 0.63 ± 1.01 | 0.87 ± 1.31 | 0.005 | NS |
|
| Proteobacteria | 0.11 ± 0.34 | 0.28 ± 0.93 | NS | 0.05 ± 0.09 | 0.17 ± 0.29 | 0.008 | NS |
|
| 0.21 ± 0.33 | 0.13 ± 0.21 | 0.059 | 0.12 ± 0.18 | 0.15 ± 0.24 | NS | NS | |
|
| Proteobacteria | 0.03 ± 0.04 | 0.04 ± 0.05 | NS | 0.04 ± 0.09 | 0.14 ± 0.25 | 0.001 | NS |
|
| Firmicutes | 0.72 ± 1.46 | 0.61 ± 1.24 | NS | 0.51 ± 1.10 | 0.66 ± 1.42 | 0.001 | NS |
|
| Proteobacteria | 0.01 ± 0.02 | 0.14 ± 0.58 | NS | 0.02 ± 0.05 | 0.03 ± 0.10 | 0.052 | NS |
|
| Euryarchaeota | 0.002 ± 0.009 | 0.062 ± 0.316 | NS | 0.053 ± 0.148 | 0.032 ± 0.095 | 0.003 | 0.012 |
|
| Proteobacteria | 0.07 ± 0.19 | 0.03 ± 0.13 | 0.044 | 0.02 ± 0.04 | 0.01 ± 0.02 | NS | NS |
|
| 0.02 ± 0.02 | 0.03 ± 0.05 | NS | 0.01 ± 0.02 | 0.02 ± 0.01 | 0.06 | 0.04 | |
|
| Firmicutes | 0.02 ± 0.03 | 0.01 ± 0.02 | 0.026 | 0.02 ± 0.05 | 0.02 ± 0.05 | NS | NS |
|
| Firmicutes | 0.02 ± 0.06 | 0.04 ± 0.12 | NS | 0.00 ± 0.01 | 0.01 ± 0.01 | 0.018 | NS |
Data are means ± SDs. ANCOVA model was used to compare outcomes adjusted for baseline value. AVO, Hass avocado group; CTRL, control group; NS, not significant.
FIGURE 3Correlation between intestinal bacteria from phylum and family level to change in weight, body composition, and metabolic and inflammatory markers from baseline to week 12. *P = 0.05, **P = 0.01, ***P = 0.001. Chol, cholesterol; CRP, C-reactive protein; HGF, hepatic growth factor; MCP, monocyte chemoattractant protein; Tchol, total cholesterol; TGF, transforming growth factor.